These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23859802)

  • 21. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCV RNA viral load assessments in the era of direct-acting antivirals.
    Cobb B; Pockros PJ; Vilchez RA; Vierling JM
    Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
    Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
    Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 30. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
    Khalilieh S; Feng HP; Hulskotte EG; Wenning LA; Butterton JR
    Clin Pharmacokinet; 2015 Jun; 54(6):599-614. PubMed ID: 25787025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].
    Nikitin IG; Baĭkova IE; Gogova LM; Volynkina VM; Kisliakov VA
    Ter Arkh; 2013; 85(2):76-84. PubMed ID: 23653945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Direct antiviral treatment strategies in chronic hepatitis C].
    Neumann-Haefelin C; Blum HE; Thimme R
    Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral agents and hepatitis C.
    Archer-Festa M; Nilsen-Kupsch S
    N Y State Dent J; 2012; 78(4):42-5. PubMed ID: 23252194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of resistance mutations against HCV ketoamide protease inhibitors.
    Tong X; Bogen S; Chase R; Girijavallabhan V; Guo Z; Njoroge FG; Prongay A; Saksena A; Skelton A; Xia E; Ralston R
    Antiviral Res; 2008 Mar; 77(3):177-85. PubMed ID: 18201776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.